A. Jo Chien

Also affiliated with University of Alabama at Birmingham, UCSF Helen Diller Family Comprehensive Cancer Center, University of San Francisco

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 26 papers. Top paper: “Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer”.

Association of Event-Free and Distant Recurrence–Free Survival With Individual-Level Pathologic Complete Response in Neoadjuvant Treatment of Stages 2 and 3 Breast Cancer

JAMA Oncology(2020)10.1001/jamaoncol.2020.2535

N/A

6.3DataRank · unranked

225 citations

Angela DeMichele, Christina Yau, Claudine Isaacs, W. Fraser Symmans, Kathy S. Albain +74 more

Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial

Annals of Oncology(2020)10.1016/j.annonc.2020.05.012

N/A

3.1DataRank · unranked

106 citations

Sara A. Hurvitz, Jack A. Di Palma, Ron Bose, A. Jo Chien, Nicholas Iannotti +48 more

Circulating tumor DNA in neoadjuvant treated breast cancer reflects response and survival

medRxiv(2020)10.1101/2020.02.03.20019760

N/A

1.6DataRank · unranked

41 citations

Lamorna Brown Swigart, Hsin-Ta Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +18 more

Datopotamab–deruxtecan plus durvalumab in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03267-1

N/A

1.4DataRank · unranked

43 citations

Meghna S. Trivedi, Christina Yau, Rita Nanda, Hope S. Rugo, Marie Davidian +55 more

Residual cancer burden after neoadjuvant chemotherapy and long-term survival outcomes in breast cancer: a multicentre pooled analysis of 5161 patients

The Lancet Oncology(2021)10.1016/s1470-2045(21)00589-1

N/A

0.917DataRank · unranked

451 citations

Marie Osdoit, Marieke van der Noordaa, Sonal Shad, Jane Wei, Diane de Croze +94 more

Circulating tumor DNA in neoadjuvant-treated breast cancer reflects response and survival

Annals of Oncology(2020)10.1016/j.annonc.2020.11.007

N/A

0.917DataRank · unranked

450 citations

Lamorna Brown Swigart, H.-T. Wu, Gillian L. Hirst, Christina Yau, Denise M. Wolf +19 more

Safety and efficacy of HSP90 inhibitor ganetespib for neoadjuvant treatment of stage II/III breast cancer

npj Breast Cancer(2022)10.1038/s41523-022-00493-z

N/A

0.900DataRank · unranked

27 citations

Andres Forero‐Torres, Douglas Yee, Christina Yau, Denise M. Wolf, John Park +44 more

Durvalumab with olaparib and paclitaxel for high-risk HER2-negative stage II/III breast cancer: Results from the adaptively randomized I-SPY2 trial

Cancer Cell(2021)10.1016/j.ccell.2021.05.009

N/A

0.873DataRank · unranked

337 citations

Christina Yau, Denise M. Wolf, Hyo S. Han, Lili Du, Anne M. Wallace +40 more

Clinical significance and biology of circulating tumor DNA in high-risk early-stage HER2-negative breast cancer receiving neoadjuvant chemotherapy

Cancer Cell(2023)10.1016/j.ccell.2023.04.008

N/A

0.777DataRank · unranked

177 citations

Lamorna Brown Swigart, Ziad Ahmed, Rosalyn W. Sayaman, Derrick Renner, Ekaterina Kalashnikova +26 more

Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trial

Nature Communications(2021)10.1038/s41467-021-26019-y

N/A

0.648DataRank · unranked

74 citations

Christina Yau, Denise M. Wolf, Emanuel F. Petricoin, L. J. van ‘t Veer, Douglas Yee +46 more

Datopotamab–deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial

Nature Medicine(2024)10.1038/s41591-024-03266-2

N/A

0.610DataRank · unranked

13 citations

Jane Meisel, Christina Yau, Hope S. Rugo, Rita Nanda, Marie Davidian +52 more

Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk

npj Breast Cancer(2021)10.1038/s41523-021-00239-3

N/A

0.598DataRank · unranked

53 citations

Wen Li, Denise M. Wolf, Christina Yau, Gillian L. Hirst, Lamorna Brown Swigart +12 more

Predicted sensitivity to endocrine therapy for stage II-III hormone receptor-positive and HER2-negative (HR+/HER2−) breast cancer before chemo-endocrine therapy

Annals of Oncology(2021)10.1016/j.annonc.2021.02.011

N/A

0.574DataRank · unranked

45 citations

Christina Yau, Lamorna Brown Swigart, Rebekah Gould, Gregor Krings, Gillian L. Hirst +27 more

Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer

npj Breast Cancer(2021)10.1038/s41523-021-00337-2

N/A

0.510DataRank · unranked

29 citations

Claudine Isaacs, Denise M. Wolf, Christina Yau, Paul Haluska, Karthik V. Giridhar +50 more

The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study

npj Breast Cancer(2021)10.1038/s41523-021-00366-x

N/A

0.483DataRank · unranked

24 citations

Amy M. Shui, Michelle Melisko, A. Jo Chien, Emi Yoshida, Elizabeth Lancaster +4 more

Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-2256

N/A

0.457DataRank · unranked

20 citations

Christina Yau, Emanuel F. Petricoin, Denise M. Wolf, Julie E. Lang, A. Jo Chien +44 more

A phase Ib trial of the cyclin-dependent kinase inhibitor dinaciclib (dina) in combination with pembrolizumab (P) in patients with advanced triple-negative breast cancer (TNBC) and response correlation with MYC-overexpression.

Journal of Clinical Oncology(2020)10.1200/jco.2020.38.15_suppl.1076

N/A

0.449DataRank · unranked

19 citations

Amelia S. Gliwa, Siti Rahmaputri, H Dittrich, Melanie Majure, Hope S. Rugo +10 more

Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.504

N/A

0.416DataRank · unranked

15 citations

Hope S. Rugo, Lajos Pusztai, Rita A. Mukhtar, A. Jo Chien, Christina Yau +7 more

Effect of Longitudinal Variation in Tumor Volume Estimation for MRI-guided Personalization of Breast Cancer Neoadjuvant Treatment

Radiology Imaging Cancer(2023)10.1148/rycan.220126

N/A

0.373DataRank · unranked

8 citations

Teffany Joy Bareng, Jessica Gibbs, Wen Li, Elissa R. Price, Bonnie N. Joe +93 more

Demographic and clinical characteristics of patients with metastatic breast cancer and leptomeningeal disease: a single center retrospective cohort study

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07339-1

N/A

0.292DataRank · unranked

6 citations

Samantha Fisch, Elene Tsopurashvili, Sai Sahitha Somepalle, Mia Salans, Harish N. Vasudevan +7 more

Pexidartinib and standard neoadjuvant therapy in the adaptively randomized I-SPY2 trial for early breast cancer

Breast Cancer Research and Treatment(2024)10.1007/s10549-024-07555-9

N/A

0.255DataRank · unranked

4 citations

Mike Campbell, Christina Yau, A. Jo Chien, Anne M. Wallace, Claudine Isaacs +18 more

Oral paclitaxel, carboplatin, and dostarlimab (OPE/Cb/D) without and with trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant I-SPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba520

N/A

0.165DataRank · unranked

2 citations

Kevin Kalinsky, Christina Yau, A. Jo Chien, Judy C. Boughey, Erica Stringer-Reasor +15 more

Oral paclitaxel and dostarlimab with or without trastuzumab in early-stage, high-risk breast cancer: Results from the neoadjuvant ISPY 2 TRIAL.

Journal of Clinical Oncology(2023)10.1200/jco.2023.41.17_suppl.lba612

N/A

0.165DataRank · unranked

2 citations

Alexandra Thomas, Christina Yau, A. Jo Chien, Carla I. Falkson, Erica Stringer-Reasor +15 more

Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.510

N/A

0.104DataRank · unranked

1 citations

Amy S. Clark, Christina Yau, Denise M. Wolf, L. J. van ‘t Veer, Emily Douglas +10 more

Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study

Breast Cancer Research(2025)10.1186/s13058-025-02121-7

N/A

0DataRank · unranked

1 citations

Michelle Jayaraj, Mia Salans, Kelsey Kuwahara, Maggie H. Zhou, Samantha Fisch +12 more

Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy

Cancers(2020)10.3390/cancers12061511

N/A

0DataRank · unranked

18 citations

Deep Hathi, Rita I. Freimanis, Rita A. Mukhtar, A. Jo Chien, Laura J. Esserman +4 more